Cargando…

Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors

Testicular germ cell tumors (TGCTs) represent the most frequent malignancy in young adult men and have one the highest heritability rates among all cancers. A recent multicenter case–control study identified CHEK2 as the first moderate-penetrance TGCT predisposition gene. Here, we analyzed CHEK2 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirchner, Kira, Seidel, Christoph, Paulsen, Finn-Ole, Sievers, Bianca, Bokemeyer, Carsten, Lessel, Davor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672725/
https://www.ncbi.nlm.nih.gov/pubmed/38002677
http://dx.doi.org/10.3390/jcm12227065
_version_ 1785149548197314560
author Kirchner, Kira
Seidel, Christoph
Paulsen, Finn-Ole
Sievers, Bianca
Bokemeyer, Carsten
Lessel, Davor
author_facet Kirchner, Kira
Seidel, Christoph
Paulsen, Finn-Ole
Sievers, Bianca
Bokemeyer, Carsten
Lessel, Davor
author_sort Kirchner, Kira
collection PubMed
description Testicular germ cell tumors (TGCTs) represent the most frequent malignancy in young adult men and have one the highest heritability rates among all cancers. A recent multicenter case–control study identified CHEK2 as the first moderate-penetrance TGCT predisposition gene. Here, we analyzed CHEK2 in 129 TGCT cases unselected for age of onset, histology, clinical outcome, and family history of any cancer, and the frequency of identified variants was compared to findings in 27,173 ancestry-matched cancer-free men. We identified four TGCT cases harboring a P/LP variant in CHEK2 (4/129, 3.10%), which reached statistical significance (p = 0.0191; odds ratio (OR), 4.06; 95% CI, 1.59–10.54) as compared to the control group. Cases with P/LP variants in CHEK2 developed TGCT almost 6 years earlier than individuals with CHEK2 wild-type alleles (5.67 years; 29.5 vs. 35.17). No association was found between CHEK2 status and further clinical and histopathological characteristics, including histological subtypes, the occurrence of aggressive TGCT, family history of TGCT, and family history of any cancer. In addition, we found significant enrichment for the low-penetrance CHEK2 variant p.Ile157Thr (p = 0.0259; odds ratio (OR), 3.69; 95% CI, 1.45–9.55). Thus, we provide further independent evidence of CHEK2 being a moderate-penetrance TGCT predisposition gene.
format Online
Article
Text
id pubmed-10672725
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106727252023-11-13 Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors Kirchner, Kira Seidel, Christoph Paulsen, Finn-Ole Sievers, Bianca Bokemeyer, Carsten Lessel, Davor J Clin Med Article Testicular germ cell tumors (TGCTs) represent the most frequent malignancy in young adult men and have one the highest heritability rates among all cancers. A recent multicenter case–control study identified CHEK2 as the first moderate-penetrance TGCT predisposition gene. Here, we analyzed CHEK2 in 129 TGCT cases unselected for age of onset, histology, clinical outcome, and family history of any cancer, and the frequency of identified variants was compared to findings in 27,173 ancestry-matched cancer-free men. We identified four TGCT cases harboring a P/LP variant in CHEK2 (4/129, 3.10%), which reached statistical significance (p = 0.0191; odds ratio (OR), 4.06; 95% CI, 1.59–10.54) as compared to the control group. Cases with P/LP variants in CHEK2 developed TGCT almost 6 years earlier than individuals with CHEK2 wild-type alleles (5.67 years; 29.5 vs. 35.17). No association was found between CHEK2 status and further clinical and histopathological characteristics, including histological subtypes, the occurrence of aggressive TGCT, family history of TGCT, and family history of any cancer. In addition, we found significant enrichment for the low-penetrance CHEK2 variant p.Ile157Thr (p = 0.0259; odds ratio (OR), 3.69; 95% CI, 1.45–9.55). Thus, we provide further independent evidence of CHEK2 being a moderate-penetrance TGCT predisposition gene. MDPI 2023-11-13 /pmc/articles/PMC10672725/ /pubmed/38002677 http://dx.doi.org/10.3390/jcm12227065 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kirchner, Kira
Seidel, Christoph
Paulsen, Finn-Ole
Sievers, Bianca
Bokemeyer, Carsten
Lessel, Davor
Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors
title Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors
title_full Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors
title_fullStr Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors
title_full_unstemmed Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors
title_short Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors
title_sort further association of germline chek2 loss-of-function variants with testicular germ cell tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672725/
https://www.ncbi.nlm.nih.gov/pubmed/38002677
http://dx.doi.org/10.3390/jcm12227065
work_keys_str_mv AT kirchnerkira furtherassociationofgermlinechek2lossoffunctionvariantswithtesticulargermcelltumors
AT seidelchristoph furtherassociationofgermlinechek2lossoffunctionvariantswithtesticulargermcelltumors
AT paulsenfinnole furtherassociationofgermlinechek2lossoffunctionvariantswithtesticulargermcelltumors
AT sieversbianca furtherassociationofgermlinechek2lossoffunctionvariantswithtesticulargermcelltumors
AT bokemeyercarsten furtherassociationofgermlinechek2lossoffunctionvariantswithtesticulargermcelltumors
AT lesseldavor furtherassociationofgermlinechek2lossoffunctionvariantswithtesticulargermcelltumors